DOCSLIB.ORG

Oral Contraceptive Reference Chart

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Oral Contraceptive Reference Chart Oral Contraceptive Reference Chart Generic Name (Tier 1) Brand Name Estrogen/Progestin Component MONOPHASIC Alesse EE 20 mcg/ Levonorgestrel 0.1 mg Aviane, Orsythia, Falmina, Lessina, (not available) Delyla, Aubra, Sronyx, Lutera, levonorgestrel/EE Ortho-Cept, EE 30 mcg/ Desogestrel 0.15 mg Apri, Solia, Reclipsen, Enskyce, Desogen Emoquette, Desogestrel/EE Nordette, EE 30 mcg/ Levonorgestrel 0.15 mg Levora, Portia, Altavera, Chateal, Kurvelo, Levlen (not available) Marlissa, Levonorgestrel/EE Lo/Ovral EE 30 mcg/ Norgestrel 0.3 mg Low-Ogestrel, Cryselle, Norgestrel/EE, Elinest Loestrin 1.5/30 EE 30 mcg/ Norethindrone 1.5 mg Junel 1.5/30, Microgestin 1.5/30, Gildess 1.5/30, Larin 1.5/30 Loestrin Fe 1.5/30 EE 30 mcg/ Norethindrone 1.5 mg/ Fe 75 mg Junel Fe 1.5/30, Microgestin Fe 1.5/30, Gildess Fe 1.5/30, Larin Fe 1.5/30 Loestrin 1/20 EE 20 mcg/ Norethindrone 1 mg Junel 1/20, Microgestin 1/20, Gildess 1/20, Larin 1/20, Norethindrone/EE Loestrin Fe 1/20 EE 20 mcg/ Norethindrone 1 mg/ Fe 75 mg Junel Fe 1/20, Microgestin Fe 1/20, Gildess Fe 1/20, Larin Fe 1/20, Norethindrone/EE/Fe, Tarina Fe Ortho-Cyclen EE 35 mcg/ Norgestimate 0.25 mg Sprintec, Previfem, MonoNessa, Norgestimate/EE, Estarylla, Mono-Linyah Ovcon-35 EE 35 mcg/ Norethindrone 0.4 mg Balziva, Zenchent, Briellyn, Philith, Gildagia, Vyfemla Femcon Fe EE 35 mcg/ Norethindrone 0.4 mg/ Fe 75 mg Zeosa, Zenchent Fe, Wymzya Fe (chew or swallow) (chew or swallow) Brevicon, Modicon EE 35 mcg/ Norethindrone 0.5 mg Necon 0.5/35, Nortrel 0.5/35, Wera 0.5/35 Ortho-Novum 1/35, EE 35 mcg/ Norethindrone 1 mg Necon 1/35, Nortrel 1/35, Cyclafem 1/35, Norinyl 1+35 Alyacen 1/35, Dasetta 1/35, Pirmella 1/35 Demulen 1/35 EE 35 mcg / Ethynodiol diacetate 1 mg Zovia 1/35E, Kelnor 1/35 (not available) Ogestrel EE 50 mcg/ Norgestrel 0.5 mg None Updated December 2014 Oral Contraceptive Reference Chart Ovcon-50 EE 50 mcg/ Norethindrone 1 mg None Zovia 1/50E EE 50 mcg/ Ethynodiol diacetate 1 mg None Norinyl 1 + 50, Mestranol 50 mcg/ Norethindrone 1 mg None Necon 1/50 Yasmin EE 30 mcg/ Drospirenone 3 mg Ocella, Syeda, Zarah, Drospirenone/EE Safyral EE 30 mcg/ Drospirenone 3 mg/ Levomefolate None *Non-formulary calcium 0.451 mg BIPHASIC Mircette EE 20, 10 mcg / Desogestrel 0.15 mg Kariva, Azurette, Viorele, Pimtrea desogestrel/EE Extended Cycle Active tablet (EE 20 mcg): 21 days Inactive tablet: 2 days Active EE only (10 mcg): 5 days Necon 10/11 EE 35 mcg/ Norethindrone 0.5, 1 mg None Extended Cycle Active tablet (Nor 0.5 mg): 10 days Active tablet (Nor 1 mg): 11 days Inactive tablet: 7 days TRIPHASIC Estrostep Fe EE 20, 30, 35 mcg/ Norethindrone 1 mg/ Fe 75 mg Tilia Fe, Tri-Legest Fe Extended Cycle Active tablet (EE 20 mcg): 5 days Active tablet (EE 30 mcg): 7 days Active tablet (EE 35 mcg): 9 days Inactive tablet (Fe only): 7 days Tri-Levlen EE 30, 40 mcg/ levonorgestrel 0.05, 0.075, 0.125mg Trivora, Enpresse, Myzilra, Levonest (not available) Extended Cycle Active tablet (EE 30, Lev 0.05): 6 days Active tablet (EE 40, Lev 0.075): 5 days Active tablet (EE 30, Lev 0.125): 10 days Inactive tablet: 7 days Ortho Tri-Cyclen EE 35 mcg/ Norgestimate 0.18, 0.215, 0.25 mg Tri-Sprintec, Trinessa, Tri-Previfem, Tri-Linyah, Tri-Estarylla, Extended Cycle Norgestimate/EE Active tablet (Nor 0.18): 7 days Active tablet (Nor 0.215): 7 days Active tablet (Nor 0.25): 7 days Inactive tablet: 7 days Updated December 2014 Oral Contraceptive Reference Chart Ortho Tri-Cyclen LO EE 25 mcg/ Norgestimate 0.18, 0.215, 0.25 mg None Extended Cycle Active tablet (Nor 0.18): 7 days Active tablet (Nor 0.215): 7 days Active tablet (Nor 0.25): 7 days Inactive tablet: 7 days Tri-Norinyl EE 35 mcg/ Norethindrone 0.5, 1 mg Aranelle , Leena Extended Cycle Active tablet (Nor 0.5): 7 days Active tablet (Nor 1): 9 days Active tablet (Nor 0.5): 5 days Inactive tablet: 7 days Cyclessa EE 25 mcg/ Desogestrel 100, 125, 150 mcg Velivet, Cesia, Caziant Extended Cycle Active tablet (Des 100): 7 days Active tablet (Des 125): 7 days Active tablet (Des 150): 7 days Inactive tablet: 7 days Ortho-Novum 7/7/7 EE 35 mcg/ Norethindrone 0.5, 0.75, 1 mg Necon 7/7/7, Nortrel 7/7/7, Cyclafem 7/7/7, Alyacen 7/7/7, Dasetta 7/7/7, Extended Cycle Pirmella 777 Active tablet (Nor 0.5): 7 days Active tablet (Nor 0.75): 7 days Active tablet (Nor 1): 7 days Inactive tablet: 7 days FOUR-PHASIC Natazia Estradiol valerate 3, 2, 1 mg/ Dienogest 2, 3 mg None Extended Cycle Active estrogen only (EV 3 mg): 2 days Active tab (EV 2mg, Dienogest 2mg): 5 days Active tab (EV 2mg, Dienogest 3mg): 17 days Active estrogen only (EV 1mg): 2 days Inactive tablet: 2 days EXTENDED-CYCLE MONOPHASIC Generess Fe EE 25 mcg/ Norethindrone 0.8 mg/ Fe 75mg None (chewable only) * Non-formulary Extended Cycle: Active tablet: 24 days Inactive tablet: 4 days Loestrin 24 Fe EE 20 mcg/ Norethindrone 1 mg/ Fe 75 mg Updated December 2014 Oral Contraceptive Reference Chart Lomedia 24 Fe, Norethindrone/EE/Fe Extended Cycle: Active tablet: 24 days Inactive tablet: 4 days Minastrin 24 Fe EE 20 mcg/ Norethindrone 1 mg/ Fe 75 mg None (chewable) Extended Cycle: Active tablet: 24 days Inactive tablet: 4 days Beyaz EE 20 mcg/ Drospirenone 3 mg/ Levomefolate None *Non-formulary calcium 0.451 mg Extended Cycle Active tablet: 24 days Inactive tablet: 4 days Yaz EE 20 mcg/ Drospirenone 3 mg Gianvi, Loryna, Vestura, Nikki Extended Cycle: Active tablet: 24 days Inactive tablet: 4 days MULTIPHASIC Lo Loestrin Fe EE 10 mcg/ Norethindrone 1 mg/ Fe 75mg None *Non-formulary Extended Cycle: Active tablet: 24 days Active EE only: 2 days Inactive tablet: 2 days Lo Minastrin Fe EE 10 mcg/ Norethindrone 1 mg/ Fe 75mg None (chewable) *Non-formulary Extended Cycle: Active tablet: 24 days Active EE only: 2 days Inactive tablet: 2 days Seasonique EE 30, 10 mcg/ Levonorgestrel 0.15 mg Amethia, Camrese, Daysee Extended Cycle: Active tablet: 84 days Active EE only (10 mcg): 7 days LoSeasonique EE 20, 10 mcg/ Levonorgestrel 0.1 mg Camrese Lo, Amethia Lo, Levonorgestrel/EE Extended Cycle: Active tablet: 84 days Active EE only (10 mcg): 7 days Seasonale EE 30 mcg/ Levonorgestrel 0.15 mg Quasense, Jolessa, Introvale, levonorgestrel/EE Extended Cycle: Active tablet: 84 days Updated December 2014 Oral Contraceptive Reference Chart Inactive tablet: 7 days Quartette EE 20, 25, 30, 10 mcg/ Levonorgestrel 0.15 mg None *Non-formulary Extended Cycle Active tablet (EE 20 mcg): 42 days Active tablet (EE 25 mcg): 21 days Active tablet (EE 30 mcg): 21 days Active EE only (10 mcg): 7 days CONTINUOUS CYCLE (no hormone-free interval) Amethyst, EE 20 mcg/ Levonorgestrel 90 mcg None Lybrel (not available ) Take daily PROGESTIN-ONLY PILLS Ortho Micronor, Norethindrone 0.35 mg Jolivette, Errin, Camila, Nora-BE, Nor-QD Heather, Jencycla, Deblitane, Sharobel, Lyza, Norlyroc, Norethindrone EMERGENCY CONTRACEPTIVES Plan B Levonorgestrel 0.75 mg (2 pills) Next Choice, levonorgestrel Take 2nd tablet 12 hours after the 1st Plan B One-Step Next Choice One Dose, My Way, Levonorgestrel 1.5 mg (1 pill) levonorgestrel Ella Ulipristal 30 mg None KEY o EE = Ethinyl Estradiol o EV = Estradiol Valerate o Fe = Ferrous Fumarate Updated December 2014 .
Load more

Recommended publications
  • Compositions Comprising Drospirenone Molecularly
    (19) & (11) EP 1 748 756 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 9/00 (2006.01) A61K 9/107 (2006.01) 29.04.2009 Bulletin 2009/18 A61K 9/48 (2006.01) A61K 9/16 (2006.01) A61K 9/20 (2006.01) A61K 9/14 (2006.01) (2006.01) (2006.01) (21) Application number: 05708751.2 A61K 9/70 A61K 31/565 (22) Date of filing: 10.03.2005 (86) International application number: PCT/IB2005/000665 (87) International publication number: WO 2005/087194 (22.09.2005 Gazette 2005/38) (54) COMPOSITIONS COMPRISING DROSPIRENONE MOLECULARLY DISPERSED ZUSAMMENSETZUNGEN AUS DROSPIRENON IN MOLEKULARER DISPERSION DES COMPOSITIONS CONTENANT DROSPIRENONE A DISPERSION MOLECULAIRE (84) Designated Contracting States: (72) Inventors: AT BE BG CH CY CZ DE DK EE ES FI FR GB GR • FUNKE, Adrian HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR D-14055 Berlin (DE) Designated Extension States: • WAGNER, Torsten AL BA HR MK YU 13127 Berlin (DE) (30) Priority: 10.03.2004 EP 04075713 (74) Representative: Wagner, Kim 10.03.2004 US 551355 P Plougmann & Vingtoft a/s Sundkrogsgade 9 (43) Date of publication of application: P.O. Box 831 07.02.2007 Bulletin 2007/06 2100 Copenhagen Ø (DK) (60) Divisional application: (56) References cited: 08011577.7 / 1 980 242 EP-A- 1 260 225 EP-A- 1 380 301 WO-A-01/52857 WO-A-20/04022065 (73) Proprietor: Bayer Schering Pharma WO-A-20/04041289 US-A- 5 569 652 Aktiengesellschaft US-A- 5 656 622 US-A- 5 789 442 13353 Berlin (DE) Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations.
    [Show full text]
  • Drospirenone-Containing Birth Control Pills (Yaz, Yasmin, Ocella, Gianvi and Their Generics)
    Drospirenone-Containing Birth Control Pills (Yaz, Yasmin, Ocella, Gianvi and their generics) Drospirenone is a progestin component of some birth control pills that does some blocking of testosterone (the "male hormone" that women have, too, and the hormone that can be a part of making acne worse). This is why drospirenone-containing birth control pills are especially good at helping acne (and why they can theoretically help hirsutism and female-pattern scalp hair loss as well). Drospirenone is also a mild diuretic and is why these birth control pills do not cause the water weight gain that some birth control pills can. Any birth control pill can theoretically help acne just by evening out hormonal fluctuations, but for many birth control pills, the effects on acne is very minimal. Which birth control pills are most likely to help acne? Some birth control pills are more like testosterone and some are less like testosterone. The ones that are less like testosterone can theoretically help acne more. The drospirenone-containing birth control pills go one step further by blocking testosterone, and may show the most benefit on clearing acne. Drospirenone is a progestin that is derived from 17-alpha-spironolactone and is chemically related to the diuretic spironolactone. Spironolactone is a diuretic (used for high blood pressure) that is sometimes used off-label for the treatment of acne, hirsutism or female-pattern hair loss. Often people say that a drospirenone-containing birth control pill may be equivalent to 25mg of spironolactone. Risks : Any estrogen-containing birth control pill increases the risk of a high blood pressure, stroke, or other life-threatening blood clot, and one study showed possibly a slightly higher risk with a drospirenone-containing birth control pill.
    [Show full text]
  • Ocps) Used in the NM Family Planning Program (FPP
    The following slides are intended to familiarize nurses and clinicians with oral contraceptive pills (OCPs) used in the NM Family Planning Program (FPP). The FPP does not intend for this information to supersede the Family Planning Protocol particularly on the requirement for Public Health Nurses in the Public Health Offices to consult a clinician as stated in the Protocol when in doubt or if it is necessary to switch the client’s OCP type. 1 2 Combined oral contraceptives (COCs) contain two hormones; estrogen and progestin. In general, any combined OCP is good for most women who are eligible to take estrogen according to the CDC U.S. Medical Eligibility Criteria (MEC). Once again, refer to the US MEC chart to find out if OCP is a suitable choice for clients with specific health conditions. To learn a little bit about what each hormone does, the FPP is providing the following summary: Estrogen: provides endometrial stability = menstrual cycle control. A higher estrogen dose increases the venous thromboembolism (VTE) or clot risk but OCP clot risk is still less harmful than the clot risk related to pregnancy and giving birth. Progestin: provides most of the contraceptive effect by ‐Preventing luteinizing hormone (LH) surge /ovulation ‐Thickening the cervical mucus to prevent sperm entry. Two major OCP formations are available. Monophasic: There is only one dose of estrogen and progestin in each active pill in the packet; and Multiphasic: There are varying doses of hormones, particularly progestin in the active pills. 3 Section 3 of the FPP Protocol contains the OCP Substitute Table, which groups OCPs into 6 classes according to the estrogen dosage, the type of progestin and the formulations.
    [Show full text]
  • Download PDF File
    Ginekologia Polska 2019, vol. 90, no. 9, 520–526 Copyright © 2019 Via Medica ORIGINAL PAPER / GYNECologY ISSN 0017–0011 DOI: 10.5603/GP.2019.0091 Anti-androgenic therapy in young patients and its impact on intensity of hirsutism, acne, menstrual pain intensity and sexuality — a preliminary study Anna Fuchs, Aleksandra Matonog, Paulina Sieradzka, Joanna Pilarska, Aleksandra Hauzer, Iwona Czech, Agnieszka Drosdzol-Cop Department of Pregnancy Pathology, Department of Woman’s Health, School of Health Sciences in Katowice, Medical University of Silesia, Katowice, Poland ABSTRACT Objectives: Using anti-androgenic contraception is one of the methods of birth control. It also has a significant, non-con- traceptive impact on women’s body. These drugs can be used in various endocrinological disorders, because of their ability to reduce the level of male hormones. The aim of our study is to establish a correlation between taking different types of anti-androgenic drugs and intensity of hirsutism, acne, menstrual pain intensity and sexuality . Material and methods: 570 women in childbearing age that had been using oral contraception for at least three months took part in our research. We examined women and asked them about quality of life, health, direct causes and effects of that treatment, intensity of acne and menstrual pain before and after. Our research group has been divided according to the type of gestagen contained in the contraceptive pill: dienogest, cyproterone, chlormadynone and drospirenone. Ad- ditionally, the control group consisted of women taking oral contraceptives without antiandrogenic component. Results: The mean age of the studied group was 23 years ± 3.23. 225 of 570 women complained of hirsutism.
    [Show full text]
  • Comparing the Effects of Combined Oral Contraceptives Containing Progestins with Low Androgenic and Antiandrogenic Activities on the Hypothalamic-Pituitary-Gonadal Axis In
    JMIR RESEARCH PROTOCOLS Amiri et al Review Comparing the Effects of Combined Oral Contraceptives Containing Progestins With Low Androgenic and Antiandrogenic Activities on the Hypothalamic-Pituitary-Gonadal Axis in Patients With Polycystic Ovary Syndrome: Systematic Review and Meta-Analysis Mina Amiri1,2, PhD, Postdoc; Fahimeh Ramezani Tehrani2, MD; Fatemeh Nahidi3, PhD; Ali Kabir4, MD, MPH, PhD; Fereidoun Azizi5, MD 1Students Research Committee, School of Nursing and Midwifery, Department of Midwifery and Reproductive Health, Shahid Beheshti University of Medical Sciences, Tehran, Islamic Republic Of Iran 2Reproductive Endocrinology Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Islamic Republic Of Iran 3School of Nursing and Midwifery, Department of Midwifery and Reproductive Health, Shahid Beheshti University of Medical Sciences, Tehran, Islamic Republic Of Iran 4Minimally Invasive Surgery Research Center, Iran University of Medical Sciences, Tehran, Islamic Republic Of Iran 5Endocrine Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Islamic Republic Of Iran Corresponding Author: Fahimeh Ramezani Tehrani, MD Reproductive Endocrinology Research Center Research Institute for Endocrine Sciences Shahid Beheshti University of Medical Sciences 24 Parvaneh Yaman Street, Velenjak, PO Box 19395-4763 Tehran, 1985717413 Islamic Republic Of Iran Phone: 98 21 22432500 Email: [email protected] Abstract Background: Different products of combined oral contraceptives (COCs) can improve clinical and biochemical findings in patients with polycystic ovary syndrome (PCOS) through suppression of the hypothalamic-pituitary-gonadal (HPG) axis. Objective: This systematic review and meta-analysis aimed to compare the effects of COCs containing progestins with low androgenic and antiandrogenic activities on the HPG axis in patients with PCOS.
    [Show full text]
  • PMBJP Product.Pdf
    Sr. Drug Generic Name of the Medicine Unit Size MRP Therapeutic Category No. Code Analgesic & Antipyretic / Muscle 1 1 Aceclofenac 100mg and Paracetamol 325 mg Tablet 10's 10's 8.00 relaxants Analgesic & Antipyretic / Muscle 2 2 Aceclofenac Tablets IP 100mg 10's 10's 4.37 relaxants Acetaminophen 325 + Tramadol Hydrochloride 37.5 film Analgesic & Antipyretic / Muscle 3 4 10's 8.00 coated Tablet 10's relaxants Analgesic & Antipyretic / Muscle 4 5 ASPIRIN Tablets IP 150 mg 14's 14's 2.70 relaxants DICLOFENAC 50 mg+ PARACETAMOL 325 mg+ Analgesic & Antipyretic / Muscle 5 6 10's 11.30 CHLORZOXAZONE 500 mg Tablets 10's relaxants Diclofenac Sodium 50mg + Serratiopeptidase 10mg Tablet Analgesic & Antipyretic / Muscle 6 8 10's 12.00 10's relaxants Analgesic & Antipyretic / Muscle 7 9 Diclofenac Sodium (SR) 100 mg Tablet 10's 10's 6.12 relaxants Analgesic & Antipyretic / Muscle 8 10 Diclofenac Sodium 25mg per ml Inj. IP 3 ml 3 ml 2.00 relaxants Analgesic & Antipyretic / Muscle 9 11 Diclofenac Sodium 50 mg Tablet 10's 10's 2.90 relaxants Analgesic & Antipyretic / Muscle 10 12 Etoricoxilb Tablets IP 120mg 10's 10's 33.00 relaxants Analgesic & Antipyretic / Muscle 11 13 Etoricoxilb Tablets IP 90mg 10's 10's 25.00 relaxants Analgesic & Antipyretic / Muscle 12 14 Ibuprofen 400 mg + Paracetamol 325 mg Tablet 10's 15's 5.50 relaxants Analgesic & Antipyretic / Muscle 13 15 Ibuprofen 200 mg film coated Tablet 10's 10's 1.80 relaxants Analgesic & Antipyretic / Muscle 14 16 Ibuprofen 400 mg film coated Tablet 10's 15's 3.50 relaxants Analgesic & Antipyretic
    [Show full text]
  • ORTHO TRI-CYCLEN® TABLETS ORTHO-CYCLEN® TABLETS (Norgestimate/Ethinyl Estradiol)
    PHYSICIANS' PACKAGE INSERT ORTHO TRI-CYCLEN® TABLETS ORTHO-CYCLEN® TABLETS (norgestimate/ethinyl estradiol) Patients should be counseled that this product does not protect against HIV infection (AIDS) and other sexually transmitted diseases. DESCRIPTION Each of the following products is a combination oral contraceptive containing the progestational compound norgestimate and the estrogenic compound ethinyl estradiol. ORTHO TRI-CYCLEN 21 Tablets and ORTHO TRI-CYCLEN 28 Tablets. Each white tablet contains 0.180 mg of the progestational compound, norgestimate (18,19-Dinor- 17-pregn-4-en-20-yn-3-one,17-(acetyloxy)-13-ethyl-, oxime,(17α)-(+)-) and 0.035 mg of the estrogenic compound, ethinyl estradiol (19-nor-17α-pregna,1,3,5(10)-trien-20-yne-3,17-diol). Inactive ingredients include lactose, magnesium stearate, and pregelatinized starch. Each light blue tablet contains 0.215 mg of the progestational compound norgestimate (18,19- Dinor-17-pregn-4-en-20-yn-3-one,17-(acetyloxy)-13-ethyl-,oxime,(17α)-(+)-) and 0.035 mg of the estrogenic compound, ethinyl estradiol (19-nor-17α-pregna,1,3,5(10)-trien-20-yne-3,17-diol). Inactive ingredients include FD & C Blue No. 2 Aluminum Lake, lactose, magnesium stearate, and pregelatinized starch. Each blue tablet contains 0.250 mg of the progestational compound norgestimate (18,19-Dinor-17- pregn-4-en-20-yn-3-one, 17-(acetyloxy)-13-ethyl-,oxime,(17α)-(+)-) and 0.035 mg of the estrogenic compound, ethinyl estradiol (19-nor-17α-pregna,1,3,5(10)-trien-20-yne-3,17-diol). Inactive ingredients include FD & C Blue No. 2 Aluminum Lake, lactose, magnesium stearate, and pregelatinized starch.
    [Show full text]
  • Pp375-430-Annex 1.Qxd
    ANNEX 1 CHEMICAL AND PHYSICAL DATA ON COMPOUNDS USED IN COMBINED ESTROGEN–PROGESTOGEN CONTRACEPTIVES AND HORMONAL MENOPAUSAL THERAPY Annex 1 describes the chemical and physical data, technical products, trends in produc- tion by region and uses of estrogens and progestogens in combined estrogen–progestogen contraceptives and hormonal menopausal therapy. Estrogens and progestogens are listed separately in alphabetical order. Trade names for these compounds alone and in combination are given in Annexes 2–4. Sales are listed according to the regions designated by WHO. These are: Africa: Algeria, Angola, Benin, Botswana, Burkina Faso, Burundi, Cameroon, Cape Verde, Central African Republic, Chad, Comoros, Congo, Côte d'Ivoire, Democratic Republic of the Congo, Equatorial Guinea, Eritrea, Ethiopia, Gabon, Gambia, Ghana, Guinea, Guinea-Bissau, Kenya, Lesotho, Liberia, Madagascar, Malawi, Mali, Mauritania, Mauritius, Mozambique, Namibia, Niger, Nigeria, Rwanda, Sao Tome and Principe, Senegal, Seychelles, Sierra Leone, South Africa, Swaziland, Togo, Uganda, United Republic of Tanzania, Zambia and Zimbabwe America (North): Canada, Central America (Antigua and Barbuda, Bahamas, Barbados, Belize, Costa Rica, Cuba, Dominica, El Salvador, Grenada, Guatemala, Haiti, Honduras, Jamaica, Mexico, Nicaragua, Panama, Puerto Rico, Saint Kitts and Nevis, Saint Lucia, Saint Vincent and the Grenadines, Suriname, Trinidad and Tobago), United States of America America (South): Argentina, Bolivia, Brazil, Chile, Colombia, Dominican Republic, Ecuador, Guyana, Paraguay,
    [Show full text]
  • BRS Pharmacology
    Pharmacology Gary C. Rosenfeld, Ph.D. Professor Department of Integrated Biology and Pharmacology and Graduate School of Biomedical Sciences Assistant Dean for Education Programs University of Texas Medical School at Houston Houston, Texas David S. Loose, Ph.D. Associate Professor Department of Integrated Biology and Pharmacology and Graduate School of Biomedical Sciences University of Texas Medical School at Houston Houston, Texas With special contributions by Medina Kushen, M.D. William Beaumont Hospital Royal Oak, Michigan Todd A. Swanson, M.D., Ph.D. William Beaumont Hospital Royal Oak, Michigan Acquisitions Editor: Charles W. Mitchell Product Manager: Stacey L. Sebring Marketing Manager: Jennifer Kuklinski Production Editor: Paula Williams Copyright C 2010 Lippincott Williams & Wilkins 351 West Camden Street Baltimore, Maryland 21201-2436 USA 530 Walnut Street Philadelphia, PA 19106 All rights reserved. This book is protected by copyright. No part of this book may be reproduced in any form or by any means, including photocopying, or utilized by any information storage and retrieval system without written permission from the copyright owner. The publisher is not responsible (as a matter of product liability, negligence or otherwise) for any injury resulting from any material contained herein. This publication contains information relating to general principles of medical care which should not be construed as specific instructions for individual patients. Manufacturers’ product information and package inserts should be reviewed for current information, including contraindications, dosages and precautions. Printed in the United States of America Library of Congress Cataloging-in-Publication Data Rosenfeld, Gary C. Pharmacology / Gary C. Rosenfeld, David S. Loose ; with special contributions by Medina Kushen, Todd A.
    [Show full text]
  • Norgestrel and Gestodene Stimulate Breast Cancer Cell Growth Through an Oestrogen Receptor Mediated Mechanism
    Br. J. Cancer (1993), 67, 945-952 '." Macmillan Press Ltd., 1993 Br. J. Cancer (1993), 67, 945-952 1993 Norgestrel and gestodene stimulate breast cancer cell growth through an oestrogen receptor mediated mechanism W.H. Catherino, M.H. Jeng & V.C. Jordan Department ofHuman Oncology, University of Wisconsin Comprehensive Cancer Center, 600 Highland Avenue, Madison, Wisconsin 53792, USA. Summary There is great concern over the long-term influence of oral contraceptives on the development of breast cancer in women. Oestrogens are known to stimulate the growth of human breast cancer cells, and this laboratory has previously reported (Jeng & Jordan, 1991) that the 19-norprogestin norethindrone could stimulate the proliferation of MCF-7 human breast cancer cells. We studied the influence of the 19-norprogestins norgestrel and gestodene compared to a 'non' 19- norprogestin medroxyprogesterone acetate (MPA) on MCF-7 cell proliferation. The 19-norprogestins stimulated proliferation at a concentration of 10-8 M, while MPA could not stimulate proliferation at concentrations as great as 3 x 10-6 M. The stimulatory activity of the 19-norprogestins could be blocked by the antioestrogen ICI 164,384, but not by the antiprogestin RU486. Transfection studies with the reporter plasmids containing an oestrogen response element or progesterone response element (vitERE-CAT, pS2ERE-CAT, and PRE15-CAT) were performed to determine the intracel- lular action of norgestrel and gestodene. The 19-norprogestins stimulated the vitERE-CAT activity maximally at 10-6 M, and this stimulation was inhibited by the addition of ICI 164,384. MPA did not stimulate vitERE-CAT activity. A single base pair alteration in the palindromic sequence of vitERE (resulting in the pS2ERE) led to a dramatic decrease in CAT expression by the 19-norprogestins, suggesting that the progestin activity required specific response element base sequencing.
    [Show full text]
  • Desogestrel-Only Pill (Cerazette)
    J Fam Plann Reprod Health Care: first published as 10.1783/147118903101197593 on 1 July 2003. Downloaded from Faculty of Family Planning and Reproductive Health Care Clinical Effectiveness Unit A unit funded by the FFPRHC and supported by the University of Aberdeen and SPCERH to provide guidance on evidence-based practice New Product Review (April 2003) Desogestrel-only Pill (Cerazette) Journal of Family Planning and Reproductive Health Care 2003; 29(3): 162–164 Evidence from a randomised trial has shown that a 75 mg (microgrammes) desogestrel pill inhibits ovulation in 97% of cycles. Thus, on theoretical grounds, we would expect the desogestrel pill to be more effective than existing progestogen- only pills (POPs). However, Pearl indices from clinical trials comparing it to a levonorgestrel POP were not significantly different. Therefore an evidence-based recommendation cannot be made that the desogestrel pill is different from other POPs in terms of efficacy, nor that it is similar to combined oral contraception (COC) in this respect. An evidence-based recommendation can be made that the desogestrel-only pill is similar to other POPs in terms of side effects and acceptability. The desogestrel-only pill is not recommended as an alternative to COC in routine practice, but provides a useful alternative for women who require oestrogen-free contraception. In clinical trials: l Ovulation was inhibited in 97% of cycles at 7 and 12 months after initiation. l The Pearl index was 0.41 per 100 woman-years, which was not significantly different from a levonorgestrel-only pill. However, the trial providing these data was too small to detect a clinically important difference.
    [Show full text]
  • Estrogen and Progestin Hormone Doses in Combined Birth Control Pills
    Estrogen and Progestin Hormone Doses in Combined Birth Control Pills Estrogen level Pill Brand Name Progestin Dose (mg) ethinyl estradiol (micrograms) 20 mcgm Alesse® levonorgestrel 0.10 Levlite® levonorgestrel 0.10 Loestrin 1/20® Fe norethindrone 1.00 acetate Mircette® desogestrel 0.15 Ortho Evra® norelgestromin 0.15 (patch) (norgestimate metabolite) phasic Estrostep® Fe norethindrone 1.0/1.0/1.0 20/30/35 mcgm acetate 30 mcgm Levlen® levonorgestrel 0.15 Levora® levonorgestrel 0.15 Nordette® levonorgestrel 0.15 Lo/Ovral® norgestrel 0.30 Desogen® desogestrel 0.15 Ortho-Cept® desogestrel 0.15 Loestrin® 1.5/30 norethindrone 1.50 acetate Yasmin® drospirenone 3.0 phasic Triphasil® levonorgestrel 0.05/0.075/0.125 30/40/30 mcgm Tri-Levlen® levonorgestrel 0.05/0.075/0.125 Trivora® levonorgestrel 0.05/0.075/0.125 35 mcgm Ortho-Cyclen® norgestimate 0.25 Ovcon-35® norethindrone 0.40 Brevicon® norethindrone 0.50 Modicon® norethindrone 0.50 Necon® norethindrone 1.00 Norethin® norethindrone 1.00 Norinyl® 1/35 norethindrone 1.00 Ortho-Novum® 1/35 norethindrone 1.00 Demulen® 1/35 ethynodiol diacetate 1.00 Zovia® 1/35E ethynodiol diacetate 1.00 phasic Ortho-Novum® norethindrone 0.50/1.00 35/35 mcgm 10/11 Jenest® norethindrone 0.50/1.00 phasic Ortho-Tri-Cyclen® norgestimate 0.15/0.215/0.25 35/35/35 mcgm Ortho-Novum® norethindrone 0.50/0.75/1.00 7/7/7 Tri-Norinyl® norethindrone 0.50/1.00/0.50 50 mcgm Necon® 1/50 norethindrone 1.00 Norinyl® 1/50 norethindrone 1.00 Ortho-Novum® 1/50 norethindrone 1.00 Ovcon-50® norethindrone 1.00 Ovral® norgestrel 0.50 Demulen® 1/50 ethynodiol diacetate 1.00 Zovia® 1/50E ethynodiol diacetate 1.00 Which pills have higher progestin side efects or cause more acne and hair growth? Each progestin has a diferent potency, milligram per milligram, in terms of progesterone efect to stop menstrual bleeding or androgen efect to stimulate acne and hair growth.
    [Show full text]